The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.
about
Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in CancerAdvances in targeted therapies and new promising targets in esophageal cancerAurora kinase A in gastrointestinal cancers: time to targetAlisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cellsAurora kinases as targets in drug-resistant neuroblastoma cellsAurora kinases in head and neck cancerPhase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.Loss of glutathione peroxidase 7 promotes TNF-α-induced NF-κB activation in Barrett's carcinogenesis.Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumorsA phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.AURKA regulates JAK2-STAT3 activity in human gastric and esophageal cancers.Issues in interpreting the in vivo activity of Aurora-AAlisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cellsThe pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cellsThe role of Dickkopf-3 overexpression in esophageal adenocarcinomaA phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia.AURKA induces EMT by regulating histone modification through Wnt/β-catenin and PI3K/Akt signaling pathway in gastric cancer.Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.Cell cycle proteins as promising targets in cancer therapyThe Aurora kinase A inhibitor TC-A2317 disrupts mitotic progression and inhibits cancer cell proliferation.Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy.Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells.APIO-EE-9 is a novel Aurora A and B antagonist that suppresses esophageal cancer growth in a PDX mouse model.Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.Alisertib promotes apoptosis and autophagy in melanoma through p38 MAPK-mediated aurora a signaling.Taxane-mediated radiosensitization derives from chromosomal missegregation on tripolar mitotic spindles orchestrated by AURKA and TPX2.The Aurora-Kinase A Phe31-Ile polymorphism as possible predictor of response to treatment in head and neck squamous cell carcinoma.Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.Systematic Analysis of Survival-Associated Alternative Splicing Signatures in Gastrointestinal Pan-Adenocarcinomas
P2860
Q26784060-EE9A9630-6ED7-4610-BD06-7EA685D07EE6Q26825957-0E35C805-CFF8-4E30-A4CE-529034D80250Q26864277-C2E35423-0ED0-48A2-B571-0DD251108ADFQ28386389-C408E126-41E4-4B90-B245-C72181030692Q28543446-CF0CE6B4-4351-418F-A84A-3217955B9CB0Q28654389-5334D24A-7E0A-4FA0-8709-C5DC2802957EQ33437992-01B508E3-8E3D-4DAB-B87C-64A3D33A50DAQ33827698-B017356C-DA1D-49E5-B732-7E2063CBCF5BQ34100865-55B2E1A4-DF61-4C5B-9A1E-CFD04DDA5AA0Q34448958-E6FE0292-9D62-463B-A6C0-A55EB994AA44Q34623325-B44D8C8C-22BE-4C58-9D84-26525BB409EDQ34964087-EF72CC68-6A02-4FCF-A23E-4156A3A6ABB5Q34977484-F4098D1E-3EDC-4599-9920-3B1D5ABA3BECQ35115300-E312087E-E53E-4BB5-9987-D906803F0970Q35889299-CE8E5F92-EF91-4664-AE54-D944E096466FQ36726212-CDF57FB5-B5CC-4BDB-BD80-EA73FDFFBEE1Q37341585-748E0667-785A-483A-8DED-7F9E5658094AQ37362863-0962B092-9355-44AE-9879-E9A5DC0DDA89Q37580388-65062517-A0BD-42FA-B59B-A78F009DD448Q37693690-390598C7-FA4C-425F-A04A-A5E6824217CCQ37709004-30500D10-CA00-4054-A775-64AE820B3FD1Q38894287-FD7E66C2-015F-4937-B84D-CE338BA18849Q39028389-5B2998DC-679F-4110-AD5D-C40B2E20809FQ41593187-91B6003C-E18A-4A40-AE7B-31F248D261E2Q47104548-94B85D87-A548-4936-8ED5-8C0C871AF899Q47119816-22229FAD-D49D-41F3-9D7D-52ABA2C493EBQ50225372-214E9016-E826-485A-B1C4-D12FE992A21FQ52645862-82E5958E-58C3-408B-AF2A-852952CB00BDQ55056081-E24642D3-31D1-405C-A17B-155810EB420FQ58766746-B5B4DC80-A9CF-46A0-B34B-AA6972427062
P2860
The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The combination of alisertib, ...... trointestinal adenocarcinomas.
@ast
The combination of alisertib, ...... trointestinal adenocarcinomas.
@en
type
label
The combination of alisertib, ...... trointestinal adenocarcinomas.
@ast
The combination of alisertib, ...... trointestinal adenocarcinomas.
@en
prefLabel
The combination of alisertib, ...... trointestinal adenocarcinomas.
@ast
The combination of alisertib, ...... trointestinal adenocarcinomas.
@en
P2093
P2860
P356
P1433
P1476
The combination of alisertib, ...... trointestinal adenocarcinomas.
@en
P2093
Abbes Belkhiri
Ahmed Katsha
Alexander Zaika
Jeffrey Ecsedy
Vikas Sehdev
Wael El-Rifai
P2860
P304
P356
10.1002/CNCR.27801
P407
P577
2012-09-12T00:00:00Z